GlassScriptPhysician profile
Anthony Clark Sims
NPI 1992786636
$6,731.36
in general payments reported to CMS, 2019-2025
46 companies · $794 in 2025
The $794 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,175 · 2020: $1,291 · 2021: $1,372 · 2022: $718 · 2023: $555 · 2024: $827 · 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,175.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,075.96 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $592.80 | 2021-2025 | Vraylar |
| Lilly USA, LLC | $522.69 | 2019-2025 | Mounjaro, Jardiance |
| Pfizer INC. | $418.74 | 2019-2025 | |
| Glaxosmithkline, LLC. | $387.13 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $303.43 | 2019-2024 | Prolia, Evenity |
| Novartis Pharmaceuticals Corporation | $284.56 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $279.27 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $249.53 | 2019-2025 | Farxiga, Airsupra |
| Merck Sharp & Dohme LLC | $243.48 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $201.54 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $184.75 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $178.35 | 2019-2020 | |
| Allergan, INC. | $159.52 | 2020 | |
| Scilex Pharmaceuticals INC. | $144.12 | 2022-2023 | Ztlido |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Sims listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.